TCR2 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

TCR2 Therapeutics

06/08/2021 15:39

* TCR2 Therapeutics Inc  TCRR.OQ  reported a quarterly adjusted
loss of 64 cents​​ per share for the quarter ended in June. The
mean expectation of ten analysts for the quarter was for a loss
of 59 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* TCR2 Therapeutics Inc's reported EPS for the quarter was a
loss of 64 cents​.
* The mean earnings estimate of analysts had fallen by
about 8.2% in the last three months.​ 
* In the last 30 days two analysts negatively revised earnings
estimates 
* TCR2 Therapeutics Inc shares had fallen by 16.4% this
quarter and lost 55.6% so far this year.
* The company reported a quarterly loss of $24.31 million.
* Wall Street's median 12-month price target for TCR2
Therapeutics Inc is $41.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 6 at 02:39 p.m.  ​All
figures in US dollars unless otherwise stated